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CONCISE REPORT
Juvenile onset systemic lupus erythematosus: a possible role for
vitamin D in disease status and bone health
CB Casella, LPC Seguro, L Takayama, D Medeiros, E Bonfa and RMR Pereira
Rheumatology, Faculdade de Medicina da Universidade de Sao Paulo, Brazil
Purpose: In juvenile onset systemic lupus erythematosus (JoSLE), evidence for the association
between vitamin D status, lupus activity, and bone health is very limited and not conclusive.
The aim of this study was, therefore, to assess in JoSLE patients the possible relevance of
vitamin D deficiency in disease and bone parameters. Methods: Fifty-seven JoSLE patients
were initially compared to 37 age, race and body mass index (BMI) -matched healthy controls.
The serum concentration of 25 hydroxyvitamin D (25OHD) was determined by radioimmuno-
assay. Patients with 25OHD deficiency (20 ng/mL) were compared to those with levels
>20 ng/mL. Disease activity was evaluated by SLE Disease Activity Index (SLEDAI). Bone
mineral density (BMD) and body composition (BC) were measured using dual-energy X-ray
absorptiometry (DXA). Results: 25OHD levels were similar in patients and controls
(21.44 7.91 vs 22.54 8.25 ng/mL, p¼ 0.519), regardless of supplementation (65% of
patients and none in controls). Thirty-one patients with 25OHD deficiency (20 ng/mL)
were further compared to the 26 JoSLE patients with levels >20 ng/mL. These two groups
were well-balanced regarding vitamin D confounding variables: age (p¼ 0.100), ethnicity
(p¼ 1.000), BMI (p¼ 0.911), season (p¼ 0.502), frequency of vitamin D supplementation
(p¼ 0.587), creatinine (p¼ 0.751), renal involvement (p¼ 0.597), fat mass (p¼ 0.764), lean
mass (p¼ 0.549), previous/current use of glucocorticoids(GC) (p¼ 1.0), immunosuppressors
(p¼ 0.765), and mean current daily dose of GC (p¼ 0.345). Patients with vitamin D deficiency
had higher SLEDAI (3.35 4.35 vs 1.00 2.48, p¼ 0.018), lower C4 levels (12.79 6.78 vs
18.38 12.24mg/dL, p¼ 0.038), lower spine BMD (0.798 0.148 vs 0.880 0.127 g/cm2,
p¼ 0.037) and whole body BMD (0.962 0.109 vs 1.027 0.098 g/cm2, p¼ 0.024).
Conclusion: JoSLE vitamin D deficiency, in spite of conventional vitamin D supplementation,
affects bone and disease activity status independent of therapy and fat mass reinforcing the
recommendation to achieve adequate levels. Lupus (2012) 21, 1335–1342.
Key words: Vitamin D; juvenile onset systemic lupus erythematosus; disease activity; bone
mineral density; body composition
Introduction
Vitamin D plays an essential role in bone health
and seems to be associated with a number of ill-
nesses, including cardiovascular, cancer, infectious
and particularly autoimmune diseases1–6 such as
multiple sclerosis, type 1 diabetes mellitus, auto-
immune thyroid disease, inﬂammatory bowel
disease, rheumatoid arthritis, systemic sclerosis
and systemic lupus erythematosus (SLE).4,7–12
Previous studies have shown a high prevalence of
vitamin D deﬁciency in adult lupus with approxi-
mately one-ﬁfth of patients having severe deﬁ-
ciency.13–16 Nevertheless, the association of
hypovitaminosis D and SLE activity remains con-
troversial with some studies demonstrating an
inverse relationship between SLE activity and
serum vitamin D concentration,17–22 while others
did not ﬁnd this association.23–26 The role of vita-
min D in bone health is known to be important in
the general population27 however this association
was not observed in adult SLE patients.23,28
Regarding body composition, fat mass was a
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relevant factor for hypovitaminosis D in auto-
immune diseases.29
In Juvenile onset SLE (JoSLE) there is no data
regarding the inﬂuence of vitamin D status in bone
health and the risk of deﬁciency was recently
demonstrated to be higher in autoimmune condi-
tions.30 Moreover, glucocorticoid (GC) may have a
regulatory eﬀect on vitamin D metabolism31 aggra-
vating this deﬁcit. The recommendation to avoid
sun exposure due to the high frequency of photo-
sensitivity and renal impairment in these patients32
may also contribute to the decreased concentration
of this hormone. Concerning disease factors the
only available study suggested a possible associ-
ation with disease activity, but the groups were
not matched for hypovitaminosis D confounding
parameters, precluding a deﬁnitive conclusion
about their ﬁnding.33 The aim of this study was,
therefore, to assess in JoSLE patients the possible
relevance of vitamin D deﬁciency in disease param-
eters and bone mineral density (BMD).
Patients and methods
Fifty-seven patients with JoSLE who fulﬁlled
the American College of Rheumatology criteria34
were consecutively selected at the Juvenile
Rheumatology Outpatient Clinic, University of
Sa˜o Paulo. Only patients with disease onset prior
to 16 years of age were included. Exclusion criteria
were renal dysfunction (creatinine clearance
<60mL/min), use of drugs that aﬀect vitamin D
metabolism such as anticoagulants and anticonvul-
sants, use of bisphosphonates and growth hor-
mone. Vitamin D supplementation is routinely
prescribed for patients under GC treatment, pred-
nisone 5mg/day or equivalent doses and patients
are uniformly advised to use sunscreen and avoid
sun exposure.
Thirty-seven healthy individuals, matched for
age, gender, BMI, and with no previous history of
diseases or drugs that aﬀect bone mass and vitamin
D metabolism, comprised the control group.
Race was deﬁned based on the self-reported race
of ascendants until the second generation by each
participant, as previously validated for the
Brazilian population.35 Those whose four grand-
parents were self-reported Caucasian were classiﬁed
as white. The presence of mixed African and
Caucasian ancestors, commonly referred to as
mixed race, was classiﬁed as non-Caucasian. In
the absence of racial information about grandpar-
ents, the participant’s race was similarly determined
by the race of parents.
Disease activity and cumulative organ damage
were evaluated by the SLE Disease Activity
Index (SLEDAI)36 and the Systemic Lupus
International Collaborating Clinics/American
College of Rheumatology (SLICC/ACR) damage
index 37 respectively. Information regarding disease
duration, current dose of GC and use of GC and
immunosuppressors were obtained by extensive
chart review and patient interview.
25-hydroxyvitamin D (25OHD) levels
The serum concentration of 25OHD was used to
measure the vitamin D reserves, in all patients
and controls, using a radioimmunoassay technique
(DiaSorin, Stillwater, Minnesota, USA). The
intra and inter-assay variation coeﬃcients in
our laboratory were 10.5% and 17.8%, respect-
ively.38 Vitamin D deﬁciency was deﬁned
as 25OHD 20 ng/mL (50 nmol/L), vitamin D
insuﬃciency as 21-29 ng/mL (52.5–72.5 nmol/L)
and suﬃciency/adequate levels as 30–100 ng/mL
(75–250 nmol/L) according to Endocrine Society
Clinical Practice Guidelines.39
Bone mineral density and body composition
measurements
BMD was measured by dual-energy X-ray absorp-
tiometry (DXA) using Hologic QDR-4500
Discovery equipment. BMD expressed as g/cm2
was obtained in the lumbar spine (L1–L4), total
femur and whole body of patients and controls.
Z-score less than 2.0 SD in lumbar spine were
deﬁned as low bone mass for chronological age.40
Measurements were performed by the same trained
technician who was certiﬁed by the International
Society of Clinical Densitometry (ISCD).
The body composition comprised lean mass, fat
mass and fat mass percentage and were also ana-
lyzed by DXA.41,42
Vertebral deformities assessment (VFA)
Thoracic and lumbar spine (T5–L4) lateral radio-
graphs were performed in the same Radiology
Division by trained operator and according to a
standardized protocol. Spine radiographs were
evaluated morphometrically by an experienced
radiologist and scored using the method described
by Genant et al. A vertebral fracture was deﬁned as
a reduction of at least 20% of the vertebral body
height.43
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Statistical analysis
Data were expressed as mean SD or percentage.
Patients and controls were compared using the
Student-t test, non parametric test or Fisher´s
exact test. Further, JoSLE patients were divided
in two groups regarding level of 25OHD (20 ng/
mL vs >20 ng/mL) and the same analysis was per-
formed. Statistical signiﬁcance was deﬁned as
p< 0.05.
Results
The demographic, anthropometric and clinical
characteristics of patients and controls are shown
in Table 1. Patients and controls had similar age
(p¼ 0.982), frequency of female gender (p¼ 0.450),
weight (p¼ 0.217), and BMI (p¼ 1.000).
The majority of JoSLE patients were under vita-
min D supplementation (64.91%) and the mean
daily dose was 428.57 409.75 UI. None of the
controls was supplemented with vitamin D. Blood
samples for vitamin D measurement were collected
during summer in the majority of JoSLE patients
(73.7%) and controls (73.0%) (Table 1). Serum
vitamin D levels and the frequency of subjects
with vitamin D deﬁciency (20 ng/mL) were similar
in patients and controls (21.44 7.91 vs
22.54 8.25 ng/mL, p¼ 0.519 and 54.4% vs
48.6%, p¼ 0.674). There was no signiﬁcant diﬀer-
ence in 25OHD levels between JoSLE patients with
and without vitamin D supplementation (19.5 6.8
vs 22.4 8.35 ng/mL, p¼ 0.183).
The mean disease duration was 7.42 5.46 years
with a mean SLEDAI score of 2.28 3.78 and six
(10.5%) patients had SLEDAI 8. The mean
SLICC/ACR damage index was 0.28 0.43. The
majority of patients (79%) were under GC therapy,
with a mean daily GC (prednisone) dose of
12.50 14.63mg and 74% were taking immuno-
suppressors (Table 1).
Comparing patients and controls, BMD was sig-
niﬁcantly reduced in the lumbar spine
(0.834 0.144 vs 0.962 0.167 g/cm2, p< 0.001),
in the total femur (0.850 0.134 vs
0.947 0.132 g/cm2, p¼ 0.001) and in the whole
body (0.991 0.109 vs 1.062 0.104 g/cm2,
p¼ 0.002). In addition, low BMD for chronological
age in the lumbar spine (Z-score -2) was found in
21 (36.84%) JoSLE patients compared to 3 (8.1%)
healthy controls, p¼ 0.002. Analysis of body com-
position revealed lower lean mass in JoSLE patients
than in controls (37.63 8.28 vs 41.95 9.60 kg,
p¼ 0.024), and a higher fat percentage
(30.95 7.46% vs 26.76 6.51%, p¼ 0.007).
Vertebral fractures were found in 8 (14%) patients,
none of the controls (p¼ 0.021) (Table 2).
Thirty-one patients with vitamin D deﬁciency
(20 ng/mL) were further compared to the 26
JoSLE with 25OHD levels >20 ng/mL. These two
groups were well balanced regarding vitamin D con-
founding variables: age (p¼ 0.100), gender
(p¼ 1.000), ethnicity (p¼ 1.000), BMI (p¼ 0.911),
season (p¼ 0.502), frequency and dose of vitamin
D supplementation (p¼ 0.586 and p¼ 0.481),
mean creatinine levels (p¼ 0.751), renal involvement
(p¼ 0.597), fat mass (p¼ 0.764), lean mass
(p¼ 0.549), previous/current use of GC (p¼ 1.000),
current use of immunosuppressors (p¼ 0.765) and
mean current daily dose of GC (p¼ 0.345).
Menarche age (12.77 2.13 vs 13.11 1.69 years,
p¼ 0.692) and disease duration (7.31 4.66 vs
7.56 6.38 years, p¼ 0.863) were alike in both
groups of patients. In addition, calcium supplemen-
tation (p¼ 0.684) and serum levels of total calcium
(p¼ 0.572), ionic calcium (p¼ 0.921) and
intact parathyroid hormone (p¼ 0.306) were com-
parable in patients with vitamin D deﬁciency (20
ng/mL) and patients with 25OHD levels>20 ng/mL
Table 1 Demographic, anthropometric, and clinical data of
juvenile onset systemic lupus erythematosus (JoSLE) patients
and controls
JoSLE
n¼ 57
Controls
n¼ 37 p
Age (years) 19.45 5.19 19.43 4.75 0.982
Gender, female (%) 80.70 72.97 0.450
Weight (kg) 57.25 12.13 60.69 14.20 0.217
BMI (kg/m2) 23.10 3.81 23.03 3.75 1.000
Vitamin D use (%) 64.91 0 <0.001
Daily dose of vitamin D (U) 428.57 409.75 N/A
Serum level of vitamin D
(ng/mL)
21.44 7.91 22.54 8.25 0.519
Season
Spring (%) 8.8 18.9
Summer (%) 73.7 73.0 0.353
Fall (%) 12.3 5.4
Winter (%) 5.3 2.7
Disease duration (years) 7.42 5.46 N/A
Disease activity (SLEDAI) 2.28 3.78 N/A
SLICC/ACR damage index 0.28 0.43 N/A
Current use of GC (%) 78.95 N/A
Current dose of GC (mg/day) 12.50 14.63 N/A
Current use of IS (%) 73.68 N/A
BMI: body mass index; GC: glucocorticoid; IS: immunosuppressor;
JoSLE: juvenile onset systemic lupus; N/A: not applicable; SLEDAI:
SLE Disease Activity Index; SLICC/ACR damage index (Systemic
Lupus International Collaborating Clinics/American College of
Rheumatology.
Data expressed as mean standard deviation or percentage.
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(Table 3). None of the patients had a history of mal-
absorption. Regarding organ involvement, only a
history of serositis (p¼ 0.013) and current hemato-
logical activity (p¼ 0.003) were signiﬁcantly diﬀer-
ent in the two groups of patients.
JoSLE patients with vitamin D deﬁciency pre-
sented higher SLEDAI activity index values
(3.35 4.35 vs 1.00 2.48, p¼ 0.018), lower com-
plement C4 levels (12.79 6.78 vs 18.38 12.24,
p¼ 0.038) and a tendency to lower C3 levels
(86.50 28.91 vs 109.00 52.42, p¼ 0.054) com-
pared to patients with 25OHD> 20 ng/mL. The
analysis of mean SLEDAI by organ group
showed a higher score for renal (0.9 1.7 vs
0 0, p¼ 0.009) and hematological activity
(0.35 0.49 vs 0 0, p¼ 0.0005) in JoSLE group
with vitamin D deﬁciency compared to those with
vitamin D> 20 ng/mL. No diﬀerence was observed
in the mean levels of ESR (12.3 10.4 vs
14.6 13.9mm/hour, p¼ 0.485) and the percentage
of patients with anti-DNA positive (16.1 vs 3.8%,
p¼ 0.205) between the two groups of JoSLE.
SLICC/ACR damage index was comparable in
both groups (0.39 0.72 vs 0.15 0.37, p¼ 0.139)
(Table 4).
Lumbar spine BMD (0.798 0.148 vs
0.880 0.127 g/cm2, p¼ 0.037) and whole body
BMD (0.962 0.109 vs 1.027 0.098 g/cm2,
p¼ 0.024) were lower in patients with vitamin D
deﬁciency (20 ng/mL) compared to those with
25OHD>20 ng/mL. Also, there was a tendency to
reduced total femur BMD in vitamin D lower
group (0.820 0.116 vs 0.893 0.154 g/cm2,
p¼ 0.062) (Table 4).
No diﬀerence was observed in the frequency of
vertebral fractures in JoSLE patients with and
without low vitamin D levels (16.1 vs. 11.5 %,
p¼ 0.715) (Table 4). Only one patient presented
symptomatic and severe vertebral fracture while
the other patients had grade 1 fractures.
Discussion
This is the ﬁrst study that demonstrated that vita-
min deﬁciency in JoSLE is associated with inferior
bone health and disease activity parameters. The
advantage of our study was that we excluded
patients with factors that may interfere with vita-
min D and bone metabolism such as renal dysfunc-
tion and bisphosphonates, anticoagulants,
anticonvulsants and growth hormone use.2 In add-
ition, matching of age, gender, race, and BMI was
essential to accurately determine if the prevalence
Table 3 Comparison of factors that may influence vitamin D
levels in juvenile onset systemic lupus erythematosus (JoSLE)
patients with serum vitamin D levels 20 ng/mL and those
with >20 ng/mL
Vitamin
D 20
n¼ 31
Vitamin D
> 20
n¼ 26 p
Age (years) 18.42 4.12 20.69 6.10 0.100
Gender, female (%) 80.6 80.8 1.000
Race, Caucasian (%) 67.7 65.4 1.000
BMI (kg/m2) 23.15 4.02 23.03 3.605 0.911
Menarche age (years) 12.77 2.13 13.11 1.69 0.692
Disease duration (years) 7.31 4.66 7.56 6.38 0.863
Season
Spring (%) 12.9 3.8 0.502
Summer (%) 74.2 73.1
Fall (%) 9.7 15.4
Winter (%) 3.2 7.7
Vitamin D use (%) 61.3 69.2 0.586
Daily dose of vitamin D
(U)
393 404.9 472 419.8 0.481
Calcium supplementation
(mg/day)
758.1 405.6 711.5 451.1 0.684
Total calcium (mg/dL) 9.2 0.4 9.1 0.7 0.572
Ionic calcium (mg/dL) 5.2 0.1 5.2 0.2 0.921
Intact parathyroid hormone
(pg/mL)
29.4 15.4 35.1 16.3 0.306
Current use of GC (%) 77 80 1.000
Current dose of GC (mg) 14.19 13.62 10.48 15.78 0.345
Current use of IS (%) 71 77 0.765
Lean mass (kg) 37.03 7.79 38.40 8.98 0.549
Fat mass (kg) 18.17 7.80 17.57 6.67 0.764
Fat percentage 31.22 8.26 30.59 6.45 0.758
BMI: body mass index; GC: glucocorticoid; IS: immunosuppressor.
Data expressed as mean standard deviation.
Table 2 Bone mineral density and body composition in
juvenile onset systemic lupus erythematosus (JoSLE) patients
and controls
JoSLE
n¼ 57
Controls
n¼ 37 p
Bone mineral density
Lumbar spine (g/cm2) 0.834 0.144 0.962 0.167 <0.001
Z-score 1.655 1.312 0.243 1.056 <0.001
Z-score<2 (%) 36.84 8.10 0.002
Total femur (g/cm2) 0.850 0.134 0.947 0.132 0.001
Whole body (g/cm2) 0.991 0.109 1.062 0.104 0.002
Body composition
Lean mass (kg) 37.63 8.28 41.95 9.60 0.024
Fat mass (kg) 17.90 7.27 16.50 6.56 0.346
Fat percentage (%) 30.95 7.46 26.76 6.51 0.007
VFA
Vertebral fracture (%) 14 0 0.021
VFA: vertebral fracture assessment.
Data expressed as mean standard deviation and percentage.
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of vitamin D deﬁciency was distinct from controls.
In this regard, the non-balanced representation of
blacks and obese individuals in children with SLE
and other rheumatologic autoimmune diseases in
the only two available studies hampers the inter-
pretation of their ﬁndings.30,33 In fact, higher con-
centration of melanin reduces vitamin D skin
production44 and bioavailability of this hormone
is decreased in overweight/obese subjects.45 Also,
most of patients collected vitamin D serum sam-
ples during the summer, since circannual rhythms
of 25 hydroxyvitamin D levels has been shown to
regulate autoimmune system and cytokine
responses.46,47
We have conﬁrmed, with adequate matching,
previous observation that serum levels and the fre-
quency of vitamin D deﬁciency were similar in
JoSLE patients and controls. However, our data
suggest that concentrations of this hormone are
actually lower in JoSLE since more than half
of patients were being supplemented. Our sample
represents a real-life situation concerning vitamin
D supplementation since it is recommended in
GC treated patients48–50 and our group routinely
prescribes this vitamin to patients taking prednis-
one in doses equal or more than 5 mg per day, or
equivalent.
Of note, vitamin D deﬁciency was associated
with higher SLE activity scores and lower
complement levels, a ﬁnding also reported in previ-
ous studies evaluating adult SLE.17–22 A study of
vitamin D in new cases of SLE showed an inverse
correlation of 25OHD concentration and the
British Isles Lupus Assessment Group (BILAG)
index score and the titers of antibodies to double-
stranded DNA at the time of diagnosis.22 A recent
study showed that seasonal declines in vitamin D
levels may trigger ﬂares in non-African American
SLE patients.51
Contrarily, four studies in adult lupus showed no
association between vitamin D levels and lupus
activity.23–26 These controversial ﬁndings may be
explained by the limited number of patients ana-
lyzed and diﬀerences in the severity of disease
activity.
Curiously, vitamin D supplementation in SLE
murine models seems to have distinct beneﬁcial or
deleterious eﬀect on lupus disease activity accord-
ing to calcium serum levels in the animals, with
some evidence that high calcium background is
required for the beneﬁcial eﬀects of vitamin
D.52,53 This might be a possible explanation for
discrepant results in the literature regarding vita-
min D and lupus activity. In our study, both
groups of patients had similar serum calcium
levels. Moreover, no history of malabsorption was
found and calcium supplementation was similar in
JoSLE patients with lower and higher vitamin D
levels (20 ng/mL vs >20 ng/mL). In fact, serum
levels of total calcium, ionic calcium and intact
parathyroid hormone were comparable in both
groups of JoSLE patients suggesting that the diﬀer-
ence in vitamin D levels was not caused by malab-
sorption or poor compliance.
Vitamin D modulates T cell, B cell and antigen-
presenting cell function, switches immune proﬁle
from Th1/Th17 to Th2/Treg and thus aﬀects
innate and adaptive immune responses.54,55
In vitro and in vivo studies of vitamin D suggest
a special role for vitamin D in B cell related dis-
orders like SLE and provide an immunologic basis
for the association of vitamin D and our ﬁnding of
greater disease activity in vitamin D deﬁcient
JoSLE.56–59 Activation of vitamin D receptor
(VDR) present in immune cells, aﬀects mRNA
expression, T cell and B cell proliferation, and anti-
body production.60 Also, naive B cells seem to be
more susceptible to vitamin D than memory B cells
and its activation by NF-kB is modulated by vita-
min D.61 Furthermore, in vitro exposure to vitamin
D inhibits proliferation and induces apoptosis of
activated B cells of SLE patients and also decreases
plasma cell generation and diﬀerentiation.
Additionally, 1alpha-hydroxylase was detected in
Table 4 Comparison of disease duration and current clinical,
laboratory, and bone parameters in juvenile onset systemic
lupus erythematosus (JoSLE) patients with serum vitamin D
levels 20 ng/mL and those with >20 ng/mL
Vitamin
D 20
n¼ 31
Vitamin
D> 20
n¼ 26 P
SLEDAI 3.35 4.35 1.00 2.48 0.018
SLICC/ACR 0.39 0.72 0.15 0.37 0.139
C3 86.50 28.91 109.00 52.42 0.054
C4 12.79 6.78 18.38 12.24 0.038
dsDNA (%) 16.1 3.8 0.205
Rash (%) 6.5 7.7 1.000
Photosensitivity (%) 9.7 7.7 1.000
Arthritis (%) 3.2 3.8 1.000
Serositis (%) 0 0 1.000
Hematological involvement (%) 29 0 0.003
CNS involvement (%) 3.2 0 1.000
Renal involvement (%) 9.7 0 0.243
BMD, lumbar spine (g/cm2) 0.798 0.148 0.880 0.127 0.037
BMD, total femur (g/cm2) 0.820 0.116 0.893 0.154 0.062
BMD, whole body (g/cm2) 0.962 0.109 1.027 0.098 0.024
Vertebral fracture (%) 16.1 11.5 0.715
BMD: bone mineral density; SLEDAI: SLE Disease Activity Index;
SLICC/ACR: Systemic Lupus International Collaborating Clinics/
American College of Rheumatology; CNS: Central Nervous System.
Data expressed as mean standard deviation.
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B cells, indicating a possible role for B cells in auto-
crine and paracrine production and response to
vitamin D.62 In a classic experiment with murine
lupus model mice supplemented with vitamin D
for 22 weeks did not develop dermatologic
lesions like alopecia, necrosis of the ear, and scab
formation and had less proteinuria than non-
supplemented mice.63 Interestingly, vitamin D deﬁ-
ciency was associated with antinuclear antibodies
(ANA) positivity in healthy controls and with
higher levels of Interferon-a and higher B cell acti-
vation in SLE patients.64 Also, vitamin D deﬁcient
SLE patients have higher levels of anti-dsDNA
antibodies.22 All these laboratory and clinical ﬁnd-
ings suggest a role for vitamin D in SLE pathogen-
esis and autoantibody production. Accordingly, we
have observed herein a higher frequency of history
of serositis and current hematological activity.
Likewise, a recent study reported that the vitamin
D receptor gene polymorphism was also associated
with serositis and hematological involvement in
Chinese SLE patients65 reinforcing the relevance
of vitamin D levels in SLE clinical manifestations.
Regarding the deleterious skeletal eﬀects of
hypovitaminosis D, little is known about the real
eﬀect of vitamin D status on bone mass and the
deﬁciency of this hormone is expected to be more
harmful for bone during BMD acquisition in ado-
lescence. Accordingly, our study demonstrated for
the ﬁrst time in JoSLE patients that this deﬁciency
was associated with poorer bone health despite
comparable current GC dose, fat body mass and
conventional vitamin D supplementation. In fact,
vitamin D status has been demonstrated to be
important for optimal BMD. Of note, this eﬀect
was particularly evident in lumbar spine suggesting
that trabecular bone susceptibility to vitamin D
deﬁciency is related to a more metabolically active
bone at this site as also observed in a three years
prospective study in Finnish girls.66
JoSLE vitamin D deﬁciency, in spite of conven-
tional vitamin D supplementation, aﬀects bone and
disease activity status independent of therapy and
fat mass reinforcing the recommendation to achieve
adequate levels to improve both conditions.
Vitamin D deﬁcient JoSLE patients may therefore
need higher doses of supplementation.
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